Introduction: We prospectively evaluated an immunosuppressive regimen consisting of rapamycin (Rapa), low-dose cyclosporine (CsA), low-dose mycophenolate mofetil (MMF), and prednisone (group 1) versus a regimen of CsA, MMF, and prednisone (group 2) in mismatched living related donor (LRD) and living unrelated donor (LUD) kidney transplantation.
Methods: Group 1 included 24 transplant recipients of eight mismatched LRD and 16 LUD, treated with Rapa, low-dose MMF, CsA, and prednisone. Group 2 included 53 transplant recipients (25 LRD, 27 LUD, and one cadaveric donor), treated with MMF, CsA, and prednisone. All patients in group 1 received a single bolus of rabbit-anti-human T-lymphocyte immune serum (ATG-Fresenius 4 to 6 mg/kg). In group 2, patients received either a single ATG or an extended ATG course (3 to 5 days postoperatively).
Results: Acute rejection occurred in one patient in group 1 (4.2%) and in five patients (9.4%) in group 2, all of which resulted in graft loss. Serum creatinine was not significantly different between the two groups.
Conclusion: The immunosuppressive protocol of Rapa, CsA, MMF, and prednisone with single-bolus induction ATG achieves excellent immunosuppression and graft survival with no apparent risks in the short and intermediate term.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2005.07.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Physician-Directed Mycophenolate Mofetil Dose Reduction After Kidney Transplantation: A Multicenter Real Word Experience.
Transplant Proc
December 2024
The William J. von Liebig Center for Transplantation and Clinical Regeneration, Rochester, Minnesota; Department of Surgery and Immunology, Mayo Clinic, Rochester, Minnesota.
Background: Mycophenolate mofetil (MMF) dose is commonly reduced after kidney transplantation (KT). This study examined MMF dosing in the first 5 years after KT to determine if a lower MMF dose impacted outcomes.
Methods: We retrospectively studied 432 recipients who underwent KT between February 2012 and February 2015 in 3 centers.
Precision in Immune Management: Balancing Steroid Exposure, Rejection Risk, and Infectious Outcomes in Adult Kidney Transplant Recipients.
J Pers Med
November 2024
Department of Surgery, Division of Multiorgan Transplant and Hepatobiliary Surgery, The University of Texas Medical Branch, Galveston, TX 77555-0609, USA.
Background/objectives: With kidney transplant immunosuppression, physicians must balance preventing rejection with minimizing infection and malignancy risks. Steroids have been a mainstay of these immunosuppression regimens since the early days of kidney transplantation, yet their risks remain debated. Our study looks at the clinical outcomes of patients undergoing early steroid withdrawal (ESW) vs.
View Article and Find Full Text PDFMycophenolate mofetil after tacrolimus for refractory clinically amyopathic dermatomyositis: a case report.
Front Pharmacol
October 2024
The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
Article Synopsis
- Dermatomyositis (DM) with anti-MDA5 antibodies, particularly when associated with rapidly progressive interstitial lung disease (RP-ILD), is considered hard to treat.
- A significant case of clinically amyopathic dermatomyositis (CADM) with RP-ILD demonstrated a poor response to conventional treatments but improved after adding mycophenolate mofetil (MMF), leading to controlled symptoms and decreased antibody levels.
- The report emphasizes the need for more research to better understand the role of inflammatory cytokines in CADM/RP-ILD and to explore MMF's potential for long-term treatment.
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Cochrane Database Syst Rev
November 2024
Cochrane Kidney and Transplant, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia.
Background: About 80% of children with steroid-sensitive nephrotic syndrome (SSNS) have relapses. Of these children, half will relapse frequently, and are at risk of adverse effects from corticosteroids. While non-corticosteroid immunosuppressive medications prolong periods of remission, they have significant potential adverse effects.
View Article and Find Full Text PDFEfficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study.
Semin Arthritis Rheum
December 2024
Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.
Introduction: Anti-synthetase syndrome (ASS) is a rare autoimmune disease characterized by the presence of anti-aminoacyl-transfer-RNA synthetase antibodies (ARS) and the involvement of muscles, skin, joints, and lungs. Despite increasing interest and evidence, optimal clinical management remains unclear due to a lack of randomized control trials. This study aims to evaluate the efficacy and safety of a treatment regimen involving early co-administration of glucocorticoids and immunosuppressants, with rapid prednisone tapering.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!